The FDA has approved a monthly intravenous (IV) maintenance dose for Leqembi, offering a more convenient treatment schedule for early Alzheimer's disease.
The FDA is set to decide on Biogen and Eisai's Leqembi for monthly intravenous maintenance in early Alzheimer's disease, potentially improving patient convenience.
The FDA cleared icobrain aria, the first AI software to detect and grade amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease, enhancing patient safety during anti-amyloid treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.